LadRx abandons aldoxorubicin marketing approval plan; lacks resources for required activities

LadRx Corp

Management determined that while 505(b)(2) approval for aldoxorubicin is possible, company lacks resources for necessary activities.
Previously on Dec 11, 2024, LadRx had announced intent to approach FDA with a proposal to use existing clinical data.
The decision effectively halts the aldoxorubicin development pathway for now.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.